FDA Approves Etrasimod for Moderately to Severely Active Ulcerative Colitis

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.

Related Keywords

Canada ,Switzerland ,Singapore ,Australia ,Mexico ,Russia ,Sweden ,Swedish ,Michael Chiorean ,European Medicines Agency ,Center At Swedish Medical ,Pfizer ,Drug Administration ,Swedish Medical ,Marketing Authorization Application ,Severely Active Ulcerative Colitis ,Versus Placebo ,Induction Therapy ,Fda ,Etrasimod ,Etrasimod Velsipity ,Velsipity ,Ulcerative Colitis ,